Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy
J. E. Wraith(Boston Children's Hospital), J Zeman(General University Hospital in Prague), Ans T. van der Ploeg(Erasmus MC), Allan M. Lund(Copenhagen University Hospital), Gunilla Malm(Karolinska University Hospital), Linda De Meırleır(Vrije Universiteit Brussel), Olaf A. Bodamer(Universitätsklinik für Kinder und Jugendpsychiatrie), Michael Beck(Eastern Illinois University), Nathalie Guffon(Hôpital Edouard Herriot), Maurizio Scarpa(Unknown)
Cited by 522
Related Papers
Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease
|New England Journal of Medicine|2019|808
Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study
|The Journal of Pediatrics|2006|364
Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease
|Journal of Medical Genetics|2015|363
Immunologic Privilege in the Central Nervous System and the Blood–Brain Barrier
|Journal of Cerebral Blood Flow & Metabolism|2012|307
Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management
|Journal of Inherited Metabolic Disease|2011|302